Zydus to receive USFDA approval for Levomilnacipran ER Capsules
Zydus Pharmaceuticals (USA) Inc. (Zydus), a subsidiary of Zydus Lifesciences, has received preliminary approval from the United States Food and Drug Administration (USFDA) to market Levomilnacipran Extended-Release Capsules, 20 mg, 40 mg, 80 mg, and 120 mg (USRLD: Fetzima Extended-Release Capsules). Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI) used to treat adults with